Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 7/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MGAM | O43451 | 2/20 | 0.38 |
| ▸ | SI | P14410 | 2/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CCR7 | P32248 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5497236 | 0.86 | CXCR2 (0.49) | CXCR2CX3CR1CCR7 | |
| SCHEMBL5494392 | 0.80 | CXCR2 (0.43) | CXCR2GAAALDH1A1POLBHTR1B | |
| SCHEMBL3852995 | 0.77 | CXCR2 (0.49) | CXCR2CCR7 | |
| SCHEMBL490197 | 0.77 | CXCR2 (0.49) | CXCR2GAAHTR1BCX3CR1KMT2A | |
| SCHEMBL5500266 | 0.77 | CXCR2 (0.53) | CXCR2HTR1BCX3CR1PKMNPSR1 | |
| SCHEMBL490086 | 0.77 | MPO (0.48) | CXCR2GAAALDH1A1POLBHTR1B | |
| SCHEMBL489580 | 0.75 | CXCR2 (0.50) | CXCR2GAAHTR1BCX3CR1KMT2A | |
| SCHEMBL3849119 | 0.73 | KDM4E (0.42) | ALDH1A1 | |
| SCHEMBL3854052 | 0.73 | CXCR2 (0.54) | CXCR2ALDH1A1HTR1BCX3CR1KMT2A | |
| SCHEMBL27890953 | 0.71 | KMT2A (0.53) | CXCR2GAAALDH1A1POLBHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1328319-B1 | 7-AMINO-2-ALKYLTHIOPTERIDIN-4-YL-AMINES FOR THE TREATMENT OF CHEMOKINE-RELATED DISEASES | ASTRAZENECA AB (SE) | 2007-01-03 | — | — | EP | disclosed |
| US-7071193-B2 | 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases | ASTRAZENECA AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20040102447-A1 | 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | disclosed |
| EP-1328319-A1 | 7-AMINO-2-ALKYLTHIOPTERIDIN-4-YL-AMINES FOR THE TREATMENT OF CHEMOKINE-RELATED DISEASES | AstraZeneca AB (SE) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002032507-A1 | 7-AMINO-2-ALKYLTHIOPTERIDIN-4-YL-AMINES FOR THE TREATMENT OF CHEMOKINE-RELATED DISEASES | ASTRAZENECA AB (SE) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102447-A1 | 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases | CXCR3, CXCR2, CCR2 | CXCR2 2/4885GAA 4368/4885ALDH1A1 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.